Logos Capital

– 858 Therapeutics has raised $60m in Series A financing.
– The round was led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
– 858 is a biotechnology company developing novel therapeutics for the treatment of cancer.
– The company’s lead program is a novel small molecule inhibitor of the PI3K/mTOR pathway that is being developed for the treatment of solid tumors that are resistant to existing therapies.
– The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies.

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.